CUTISS AG announces additional Member of the Board of Directors
Zurich, Switzerland, May 28 2020 – CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has further enhanced its Board of Directors with Gerard Ber as newly elected, additional and independent Member of the Board.
At the recent Annual Shareholder Meeting 2020 of CUTISS, Dr. Gerard Ber was elected as additional and independent Member of the Board of the Company for a term of one year, thus further strengthening its Board of Directors. Gerard has been acting as Co-Founder, Chief Operating Officer and Member of the Board of Advanced Accelerator Applications, an innovative radiopharmaceutical Company based in France that was acquired by Novartis in 2018. Before, he held positions as Export Area Manager for Western Europe at OM Pharma Switzerland (Vifor Pharma) in Geneva and Director of Marketing and Commerce for CIS Bio International/ORIS in Paris. Today, Gerard is Life Science Entrepreneur and Member of the Board of Directors of, among others, Ymabs (New York). He studied Pharmacy at the University of Grenoble (France). Dr. Gerard Ber is a Swiss citizen.
Daniela Marino, CEO and Co-Founder of CUTISS AG, commented: “We are pleased and honored that Gerard Ber has accepted becoming an independent Member of our Board, thereby offering his valuable and broad know-how of the Life Science industry to our emerging Company.”
About CUTISS AG
CUTISS is a Swiss Life Science Company, spin-off of the University of Zurich, developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its lead product candidate, denovoSkin™, has been tested in a phase I clinical trial on pediatric patients at the University Children’s Hospital in Zurich. Phase II studies are currently ongoing in Switzerland and the European Union and are partially funded by Wyss Zurich. denovoSkin™ has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™ aims to improve life quality of elective (reconstructive treatments) patients as well and it can further be developed in terms of complexity by adding pigmentation.
CUTISS AG, CEO Daniela Marino, +41 76 230 80 46, email@example.com, www.cutiss.swiss